United States Gastric Cancer Diagnostic Procedure Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Healthcare Providers, Symptom Types, Body Fluid, Procedures, Offerings, and Disease Indication

Description

List of Tables

The United States gastric cancer diagnostic procedure market size is expected to reach US$ 637.84 million by 2028 from US$ 481.37 million in 2022. The market is estimated to record a CAGR of 4.8% from 2022 to 2028.

The rising prevalence of gastrointestinal diseases and the growing geriatric population in the US are contributing to the growth of the United States gastric cancer diagnostic procedure market size. However, the shortage of medical laboratory professionals is hampering the market growth.

Rising Geriatric Population in US Drives United States Gastric Cancer Diagnostic Procedure Market Growth

As per the Fact Sheet: Aging in the United States, the number of people aged 65 and above is estimated to increase from 52 million in 2018 to 95 million by 2060. Additionally, the 65-year-old age group's share of the total population will increase from 16% in 2018 to 23% by 2060. Further, as per the US Census Bureau, all the baby boomers will be older than 65 years in the US by 2030 and will hold 21% of the population. It also mentioned that by 2060, around one in four people in the US will be aged 65 years and above, the number of people aged 85 and above will triple, and the country will add half a million centenarians. The prevalence of gastrointestinal disorders is high in the adult and elderly populations. As the aging population rises, the disease burden also increases. Thus, an increasing aging population propels the demand for gastric cancer diagnostics, thereby bolstering the growth of the gastric cancer diagnostic procedure market.

Based on symptom type, the United States gastric cancer diagnostic procedure market is bifurcated into symptomatic and asymptomatic. The asymptomatic segment held a larger share of the market in 2022. However, the symptomatic segment is anticipated to register a higher CAGR in the market during the forecast period. The symptoms of the early stages of gastric cancer may include indigestion, stomach discomfort, bloating, mild nausea, appetite loss, and heartburn. The advanced stages of gastric cancer show symptoms such as blood in the stool, vomiting, weight loss, stomach pain, jaundice, ascites (build-up of fluid in the abdomen), and trouble swallowing. Based on healthcare providers, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, others. In 2022, the hospitals segment held the largest share of the United States gastric cancer diagnostic procedure market. The market for the cancer research institutes segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, by body fluid, is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. In 2021, the blood segment held the largest share of the market. However, the market for the tissue segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on procedures, is segmented into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics and immunoassays, and others. In 2021, the imaging tests segment held the largest share of the market. The market for the biopsy and tissue tests segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on offerings, is segmented into instruments, reagents and consumables, and services. In 2021, the reagents and consumables segment held the largest share of the market. The market for the services segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on disease indication, is segmented into early gastric cancer and advanced gastric cancer. In 2021, the advanced gastric cancer segment held a larger share of the market. The market for the same segment is expected to grow at a higher rate in the coming years.

The International Foundation for Gastrointestinal Disorders, American Institute for Cancer Research, Centers for Disease Control and Prevention, U.S. Census Bureau, and Population Reference Bureau are among the major primary and secondary sources referred to while preparing the report on the United States gastric cancer diagnostic procedure market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the United States gastric cancer diagnostic procedure market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the United States gastric cancer diagnostic procedure market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Product Code: TIPRE00029824

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Gastric Cancer Diagnostic Procedure Market - By Healthcare Providers
- 1.3.2 Gastric Cancer Diagnostic Procedure Market - By Symptom Types
- 1.3.3 Gastric Cancer Diagnostic Procedure Market - By Body Fluid
- 1.3.4 Gastric Cancer Diagnostic Procedure Market - By Procedures
- 1.3.5 Gastric Cancer Diagnostic Procedure Market - By Offerings
- 1.3.6 Gastric Cancer Diagnostic Procedure Market - By Disease Indication
- 1.3.7 Gastric Cancer Diagnostic Procedure Market - By Country

2. Gastric Cancer Diagnostic Procedure Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Gastric Cancer Diagnostic Procedure Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 US - PEST Analysis
4.3 Expert Opinion
4.4 Gastric Cancer Prevalence Statistics
4.5 Pre-Diagnosis Workflow
4.6 Post-Diagnosis Workflow

5. United States Gastric Cancer Diagnostic Procedure Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
- 5.1.2 Growing Geriatric Population in US
5.2 Market Restraints
- 5.2.1 Shortage of Medical Laboratory Professionals
5.3 Market Opportunities
- 5.3.1 Rising Awareness on Gastric Cancer
5.4 Future Trends
- 5.4.1 Development of AI-Based Gastric Cancer Diagnostic Platform
5.5 Impact Analysis

6. Gastric Cancer Diagnostic Procedure Market - US Analysis

6.1 United States Gastric Cancer Diagnostic Procedure Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players

7. United States Gastric Cancer Diagnostic Procedure Market Analysis - by Healthcare Providers

7.1 Overview
7.2 Diagnostic Laboratories
- 7.2.1 Overview
- 7.2.2 Diagnostic Laboratories: United States Gastric Cancer Diagnostic Procedure Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.2.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Diagnostic Laboratories, by Type, 2019-2028 (US$ Million)
7.3 Hospitals
- 7.3.1 Overview
- 7.3.2 Hospitals: United States Gastric Cancer Diagnostic Procedure Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Hospitals, by Type, 2019-2028 (US$ Million)
7.4 Cancer Research Institutes
- 7.4.1 Overview
- 7.4.2 Cancer Research Institutes: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Cancer Research Institutes, by Type, 2019-2028 (US$ Million)
7.5 Oncology Specialty Clinics
- 7.5.1 Overview
- 7.5.2 Oncology Specialty Clinics: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Oncology Specialty Clinics, by Type, 2019-2028 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Others, by Type, 2019-2028 (US$ Million)

8. United States Gastric Cancer Diagnostic Procedure Market Analysis - by Symptom Type

8.1 Overview
8.2 Symptomatic
- 8.2.1 Overview
- 8.2.2 Symptomatic: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)
8.3 Asymptomatic
- 8.3.1 Overview
- 8.3.2 Asymptomatic: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)

9. United States Gastric Cancer Diagnostic Procedure Market Analysis - by Body Fluid

9.1 Overview
9.2 Blood
- 9.2.1 Overview
- 9.2.2 Blood: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)
9.3 Urine
- 9.3.1 Overview
- 9.3.2 Urine: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)
9.4 Saliva
- 9.4.1 Overview
- 9.4.2 Saliva: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)
9.5 Stomach Wash/Gastric Juice
- 9.5.1 Overview
- 9.5.2 Stomach Wash/Gastric Juice: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)
9.6 Tissue
- 9.6.1 Overview
- 9.6.2 Tissue: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)
9.7 Other
- 9.7.1 Overview
- 9.7.2 Other: Gastric Cancer Diagnostic Procedure Market- Revenue and Forecast to 2028 (US$ Million)

10. United States Gastric Cancer Diagnostic Procedure Market Analysis - by Procedures

10.1 Overview
10.2 Endoscopic Procedure
- 10.2.1 Overview
- 10.2.2 Endoscopic Procedure: United States Gastric Cancer Diagnostic Procedure Market - Revenue and Forecast to 2028 (US$ Million)
  - 10.2.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Endoscopic Procedures, by Type, 2019-2028 (US$ Million)
10.3 Biopsy and Tissue Tests
- 10.3.1 Overview
- 10.3.2 Biopsy and Tissue Tests: United States Gastric Cancer Diagnostic Procedure Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Lab Tests
- 10.4.1 Overview
- 10.4.2 Lab Tests: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 10.4.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Lab Tests, by Type, 2019-2028 (US$ Million)
10.5 In-Vitro Diagnostic Tests
- 10.5.1 Overview
- 10.5.2 In-Vitro Diagnostic Tests: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 10.5.2.1 United States Gastric Cancer Diagnostic Procedure Market, by In-Vitro Diagnostic Tests, by Type, 2019-2028 (US$ Million)
10.6 Imaging Tests
- 10.6.1 Overview
- 10.6.2 Imaging Tests: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 10.6.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Imaging Tests, by Type, 2019-2028 (US$ Million)
10.7 Molecular Diagnostics
- 10.7.1 Overview
- 10.7.2 Molecular Diagnostics: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
  - 10.7.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Molecular Diagnostic, by Type, 2019-2028 (US$ Million)
10.8 Multiplexing Molecular Diagnostics and Immunoassay
- 10.8.1 Overview
- 10.8.2 Multiplexing Molecular Diagnostics and Immunoassay: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
10.9 Others
- 10.9.1 Overview
- 10.9.2 Others: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)

11. United States Gastric Cancer Diagnostic Procedure Market Analysis - by Offerings

11.1 Overview
11.2 Instruments
- 11.2.1 Overview
- 11.2.2 Instruments: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
11.3 Reagents and Consumables
- 11.3.1 Overview
- 11.3.2 Reagents and Consumables: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
11.4 Services
- 11.4.1 Overview
- 11.4.2 Services: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)

12. United States Gastric Cancer Diagnostic Procedure Market Analysis - by Disease Indication

12.1 Overview
12.2 Early Gastric Cancer
- 12.2.1 Overview
- 12.2.2 Early Gastric Cancer: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)
12.3 Gastric Cancer Advanced Types
- 12.3.1 Overview
- 12.3.2 Gastric Cancer Advanced Types: United States Gastric Cancer Diagnostic Procedures Market - Revenue and Forecast to 2028 (US$ Million)

13. United States Gastric Cancer Diagnostic Procedure Market: Impact Assessment of COVID-19 Pandemic

13.1 US: Impact Assessment of COVID-19 Pandemic

14. United States Gastric Cancer Diagnostic Procedure Market - Industry Landscape

14.1 Overview
14.2 Growth Strategies in United States Gastric Cancer Diagnostic Procedure Market (%)
14.3 Organic Developments
- 14.3.1 Overview
14.4 Inorganic Developments
- 14.4.1 Overview

15. Company Profiles

15.1 Atlas-Link Biotech Co Ltd
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Bio-Rad Laboratories Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 MiRXES Pte Ltd
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Agilent Technologies Inc
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 F. Hoffmann-La Roche Ltd
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 bioMerieux SA
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Thermo Fisher Scientific Inc
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 Illumina Inc
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 Vela Diagnostics Holding Pte Ltd
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 Myraid Genetics Inc
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms